Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Probiotics in late infancy reduce the incidence of eczema : A randomized controlled trial. / Schmidt, Rikke Meineche; Laursen, Rikke Pilmann; Bruun, Signe; Larnkjær, Anni; Mølgaard, Christian; Michaelsen, Kim F.; Høst, Arne.

I: Pediatric Allergy and Immunology, Bind 30, Nr. 3, 2019, s. 335-340.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Schmidt, RM, Laursen, RP, Bruun, S, Larnkjær, A, Mølgaard, C, Michaelsen, KF & Høst, A 2019, 'Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial', Pediatric Allergy and Immunology, bind 30, nr. 3, s. 335-340. https://doi.org/10.1111/pai.13018

APA

Schmidt, R. M., Laursen, R. P., Bruun, S., Larnkjær, A., Mølgaard, C., Michaelsen, K. F., & Høst, A. (2019). Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. Pediatric Allergy and Immunology, 30(3), 335-340. https://doi.org/10.1111/pai.13018

Vancouver

Schmidt RM, Laursen RP, Bruun S, Larnkjær A, Mølgaard C, Michaelsen KF o.a. Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. Pediatric Allergy and Immunology. 2019;30(3):335-340. https://doi.org/10.1111/pai.13018

Author

Schmidt, Rikke Meineche ; Laursen, Rikke Pilmann ; Bruun, Signe ; Larnkjær, Anni ; Mølgaard, Christian ; Michaelsen, Kim F. ; Høst, Arne. / Probiotics in late infancy reduce the incidence of eczema : A randomized controlled trial. I: Pediatric Allergy and Immunology. 2019 ; Bind 30, Nr. 3. s. 335-340.

Bibtex

@article{26b6034a457d469ab2419ca2ba0ad253,
title = "Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial",
abstract = "Background: Allergic diseases are common and represent a considerable health and economic burden worldwide. We aimed to examine the effect of a combination of two probiotic strains administered in late infancy and early childhood on the development of allergic diseases and sensitization.Methods: In this double-blind, placebo-controlled intervention trial, participants were randomized to receive a daily mixture of Lactobacillus rhamnosus and Bifidobacterium animalis subsp lactis or placebo-starting prior to attending day care. The intervention period was 6 months, and the parents answered web-based questionnaires on allergic symptoms and doctor's diagnosed allergic disease monthly. IgE was measured at baseline and follow-up.Results: A total of 290 participants were randomized: 144 in the probiotic group and 146 in the placebo group. Mean age at intervention start was 10.1 months. At follow-up (mean age 16.1 months), the incidence of eczema was 4.2{\%} in the probiotic group and 11.5{\%} in the placebo group (P = 0.036). The incidence of asthma and conjunctivitis did not differ between groups, and no children presented with rhinitis. Sensitization was equal in the two groups at intervention start (7.5{\%} and 9.5{\%}, respectively), and two children in each group were sensitized during the intervention.Conclusions: We observed a significantly lower incidence of eczema in the probiotic group compared to the placebo group. The probiotics were administered in late infancy-prior to attending day care-suggesting a broader window of opportunity using probiotics in the prevention of eczema. The incidence of asthma, rhinitis, conjunctivitis, and sensitization did not differ.",
keywords = "Faculty of Science, Allergic diseases, Allergy, Atopy, Bifidobacterium animalis subsp lactis, Lactobacillus rhamnosus, RCT, Sensitization",
author = "Schmidt, {Rikke Meineche} and Laursen, {Rikke Pilmann} and Signe Bruun and Anni Larnkj{\ae}r and Christian M{\o}lgaard and Michaelsen, {Kim F.} and Arne H{\o}st",
note = "CURIS 2019 NEXS 070 {\circledC} 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2019",
doi = "10.1111/pai.13018",
language = "English",
volume = "30",
pages = "335--340",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Probiotics in late infancy reduce the incidence of eczema

T2 - A randomized controlled trial

AU - Schmidt, Rikke Meineche

AU - Laursen, Rikke Pilmann

AU - Bruun, Signe

AU - Larnkjær, Anni

AU - Mølgaard, Christian

AU - Michaelsen, Kim F.

AU - Høst, Arne

N1 - CURIS 2019 NEXS 070 © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2019

Y1 - 2019

N2 - Background: Allergic diseases are common and represent a considerable health and economic burden worldwide. We aimed to examine the effect of a combination of two probiotic strains administered in late infancy and early childhood on the development of allergic diseases and sensitization.Methods: In this double-blind, placebo-controlled intervention trial, participants were randomized to receive a daily mixture of Lactobacillus rhamnosus and Bifidobacterium animalis subsp lactis or placebo-starting prior to attending day care. The intervention period was 6 months, and the parents answered web-based questionnaires on allergic symptoms and doctor's diagnosed allergic disease monthly. IgE was measured at baseline and follow-up.Results: A total of 290 participants were randomized: 144 in the probiotic group and 146 in the placebo group. Mean age at intervention start was 10.1 months. At follow-up (mean age 16.1 months), the incidence of eczema was 4.2% in the probiotic group and 11.5% in the placebo group (P = 0.036). The incidence of asthma and conjunctivitis did not differ between groups, and no children presented with rhinitis. Sensitization was equal in the two groups at intervention start (7.5% and 9.5%, respectively), and two children in each group were sensitized during the intervention.Conclusions: We observed a significantly lower incidence of eczema in the probiotic group compared to the placebo group. The probiotics were administered in late infancy-prior to attending day care-suggesting a broader window of opportunity using probiotics in the prevention of eczema. The incidence of asthma, rhinitis, conjunctivitis, and sensitization did not differ.

AB - Background: Allergic diseases are common and represent a considerable health and economic burden worldwide. We aimed to examine the effect of a combination of two probiotic strains administered in late infancy and early childhood on the development of allergic diseases and sensitization.Methods: In this double-blind, placebo-controlled intervention trial, participants were randomized to receive a daily mixture of Lactobacillus rhamnosus and Bifidobacterium animalis subsp lactis or placebo-starting prior to attending day care. The intervention period was 6 months, and the parents answered web-based questionnaires on allergic symptoms and doctor's diagnosed allergic disease monthly. IgE was measured at baseline and follow-up.Results: A total of 290 participants were randomized: 144 in the probiotic group and 146 in the placebo group. Mean age at intervention start was 10.1 months. At follow-up (mean age 16.1 months), the incidence of eczema was 4.2% in the probiotic group and 11.5% in the placebo group (P = 0.036). The incidence of asthma and conjunctivitis did not differ between groups, and no children presented with rhinitis. Sensitization was equal in the two groups at intervention start (7.5% and 9.5%, respectively), and two children in each group were sensitized during the intervention.Conclusions: We observed a significantly lower incidence of eczema in the probiotic group compared to the placebo group. The probiotics were administered in late infancy-prior to attending day care-suggesting a broader window of opportunity using probiotics in the prevention of eczema. The incidence of asthma, rhinitis, conjunctivitis, and sensitization did not differ.

KW - Faculty of Science

KW - Allergic diseases

KW - Allergy

KW - Atopy

KW - Bifidobacterium animalis subsp lactis

KW - Lactobacillus rhamnosus

KW - RCT

KW - Sensitization

U2 - 10.1111/pai.13018

DO - 10.1111/pai.13018

M3 - Journal article

C2 - 30790361

VL - 30

SP - 335

EP - 340

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 3

ER -

ID: 213854377